

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO
THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Pressemitteilung

Obligationen der Basilea mit einem Gesamtnennbetrag von ungefähr CHF 47 Millionen angedient

Basel, Schweiz, 17. Juli 2020

Nach dem Ende der Angebotsfrist am 16. Juli 2020, 16.00 Uhr (MESZ), gibt Basilea Pharmaceutica AG („Basilea“ oder die „Gesellschaft“) heute die ersten Ergebnisse ihres Teilrückkaufangebots („Rückkaufangebot“) für mindestens CHF 90 Millionen und höchstens CHF 110 Millionen Nennwert ihrer ausstehenden Wandelanleihen mit Fälligkeit 2022 (ISIN: CH0305398148; SSN: 30'539'814, die „Anleihen“ und jeder Anleihenstitel die „Obligation“) wie folgt bekannt („Erste Ergebnispublikation“):

Anzahl der angedienten Obligationen mit Nennwert von je CHF 5'000	9'417
Gesamtnennwert der angedienten Obligationen	CHF 47'085'000

Die Gesellschaft gab zuvor bekannt, dass sie vorrangige ungesicherte Wandelanleihen in Höhe von CHF 125 Millionen mit Fälligkeit 2027 (die „Neuen Anleihen“) platziert und vorläufig zugeteilt hat.

Das Ergebnis des Rückkaufangebots von ungefähr CHF 47 Millionen angedienter Anleihen liegt unter dem Schwellenwert von mindestens CHF 90 Millionen anzudienender Anleihen (Bedingung der Mindestandienungsschwelle), welcher im Inserat des Rückkaufangebots publiziert ist.

Die Gesellschaft evaluiert derzeit Ansätze zur Erreichung des Ziels, das Fälligkeitsprofil ihres Fremdkapitals wie geplant zu verlängern. Sie wird am Abend des 17. Juli 2020 bekannt geben, ob das Rückkaufangebot und die Ausgabe Neuer Anleihen abgebrochen werden oder ob auf die Bedingung der Mindestandienungsschwelle verzichtet und das Angebotsvolumen der Neuen Anleihen reduziert wird.

Über Basilea

Basilea Pharmaceutica AG ist ein biopharmazeutisches Unternehmen mit vermarkteten Produkten, das sich auf die Entwicklung von Medikamenten zur Lösung der medizinischen Herausforderungen in den Therapiebereichen Onkologie und Infektionskrankheiten fokussiert. Basilea hat zwei vermarktete Produkte im Portfolio und erforscht, entwickelt und vermarktet innovative Medikamente für Patienten, die an schweren und lebensbedrohlichen Krankheiten leiden. Basilea Pharmaceutica AG hat ihren Hauptsitz in Basel, Schweiz, und ist an der Schweizer Börse SIX Swiss Exchange kotiert (SIX: BSLN). Für weitere Informationen besuchen Sie bitte die Unternehmens-Website www.basilea.com.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Disclaimer

This Repurchase Offer does not constitute an offer or an invitation to participate in the Repurchase Offer in any jurisdiction in which, or to any person to or from which, it is unlawful to make such invitation or for there to be such participation under applicable securities laws. The distribution of this press release in certain jurisdictions may be restricted by law. Persons into whose possession this press release comes are required to inform themselves about, and to observe, any such restrictions.

No action has been or will be taken in any jurisdiction in relation to the Repurchase Offer that would permit a public offering of securities in any such jurisdiction.

United States

The Repurchase Offer is not being made, and will not be made, directly or indirectly, in or into, or by use of the mail of, or by any means or instrumentality of interstate commerce of or of any facilities of a national securities exchange of, the United States or to or for the account or benefit of, U.S. persons as defined in Regulation S of the Securities Act (each a "U.S. person"). This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone and the internet and other forms of electronic communication. The Bonds may not be tendered for purchase pursuant to the Repurchase Offer by any such use, means, instrumentality or facility from or within the United States or by any persons located or resident in the United States as defined in Regulation S of the U.S. Securities Act of 1933, as amended (the "Securities Act") or to U.S. persons. Accordingly, copies of the Repurchase Offer Notice and any other documents or materials relating to the Repurchase Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to persons located or resident in the United States or to U.S. persons. Any purported offers to tender Bonds pursuant to the Repurchase Offer resulting, directly or indirectly, from a violation of these restrictions will be invalid, and any purported tender of Bonds made by a U.S. person, a person located or resident in the United States or from within the United States or from any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States or any U.S. person will not be accepted.

Each Bondholder participating in the Repurchase Offer will represent to the Offeror, the Joint Dealer Managers and the Tender Agent that it is not located or resident in the United States and is not a U.S. person and is not giving an order to participate in the Repurchase Offer from within the United States or on behalf of a U.S. person.

United Kingdom

The communication of the Repurchase Offer Notice and any other documents or materials relating to the Repurchase Offer is not being made and such documents and/or materials have

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, such documents and/or materials are not being distributed to, are not directed at and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to persons within the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order")) or falling within Article 43(2) of the Order, or to other persons to whom it may lawfully be communicated (together "relevant persons"). The investment activity to which this document relates will only be engaged in with relevant persons and persons who are not relevant persons should not rely on it.

European Economic Area

In any Member State of the European Economic Area (the "EEA") or in the United Kingdom (each, a "Relevant State"), the Repurchase Offer is only addressed to, and is only directed at, qualified investors in that Relevant State within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). Each person in a Relevant State who receives any communication in respect of the Repurchase Offer contemplated in the Repurchase Offer Notice will be deemed to have represented, warranted and agreed to and with the Joint Dealer Managers, the Tender Agent and the Company that it is a qualified investor within the meaning of the Prospectus Regulation. The Bonds have not been admitted to trading on a regulated market in the European Economic Area or in the United Kingdom.

Switzerland and General

This document and the Repurchase Offer Notice neither constitute a prospectus within the meaning of Articles 652a and 1156 of the Swiss Code of Obligations (as in effect immediately prior to the entry into force of the FinSA) nor a prospectus within the meaning of the listing rules of the SIX Swiss Exchange, a prospectus within the meaning of the FinSA or under any other applicable laws.

Für weitere Informationen kontaktieren Sie bitte:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations

Telefon +41 61 606 1102

E-Mail media_relations@basilea.com
investor_relations@basilea.com

Diese Pressemitteilung ist unter www.basilea.com abrufbar.